



SuperGen Identifies New Class of Etk/Bmx Kinase Inhibitors

DUBLIN, Calif., Apr 21, 2009 (BUSINESS WIRE) -- SuperGen Inc., (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced as part of a series of presentations at the 100th Annual Meeting of the American Association for Cancer Research (AACR), that it has identified a new class of small molecules which successfully inhibit Etk/Bmx kinase in preclinical cancer models (Abstract No. 3745).

Entitled, "**Targeting Etk/Bmx kinase with small molecule inhibitors**," the poster highlights data indicating that SuperGen lead compounds in this class inhibit the autophosphorylation of Etk, the activation of STAT3 downstream of EGF stimulation, and inhibit the colony formation of prostate and liver cancer cells lines in soft agar.

"SuperGen is committed to bringing first in class drugs into the clinic against cancer drug targets, and Etk/Bmx represents another one of these targets," said Dr. David Bearss, SuperGen's Chief Scientific Officer. "We are excited about selecting a clinical candidate for this program and think this program signifies another example of what our company and drug discovery technology can accomplish."

Copies of the 2009 AACR Annual Meeting poster presentations will be available in the pipeline section of SuperGen's Web site www.supergen.com.

About SuperGen

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit <http://www.supergen.com>.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

SOURCE: SuperGen Inc.

SuperGen, Inc.
Timothy L. Enns, 925-560-2810
SVP, Corporate Communications & Business Development
tenns@supergen.com
Susanna Chau, 925-560-2845
Investor Relations Manager
schau@supergen.com